This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Proactive Investors' CEO Sessions provide investors with an opportunity to learn about new companies and new investment opportunities and next week’s events in Sydney and Melbourne will feature four companies.
SFRRF SNDFY VRX PVE SFR ATC WRM
Po Valley Energy Limited (ASX:PVE) chairman Michael Masterman will update investors on the company’s Italian oil and gas strategy when he presents at this month’s Proactive CEO Sessions.
Australia's Po Valley Energy Limited, (“Po Valley” or “The Company”) is pleased to provide its Quarterly Activities Report for the period ending 30 June 2018, covering the Company's gasexploration, development and production outcomes across its onshore and near offshore energy assets in northern Italy.
2018-05-30 proactiveinvestors.com.au - 1
Po Valley Energy Limited (ASX:PVE) chairman Michael Masterman speaks to Proactive Investors, as the oil and gas E&P company completes the milestone of submitting a production concession application to Italian officials to proceed with full commercial production from its Selva Malvezzi gas field.
Australia's Po Valley Energy Limited, (“Po Valley” or “The Company”) is pleased to provide its Quarterly Activities Report for the period ending 31 March 2018, including substantially higher gas production volumes and gas sales revenue
SOU PVE SNEGF
Po Valley Energy Limited (ASX:PVE) chairman Michael Masterman speaks to Proactive Investors about the company's transformational year, coinciding with the release of Quarterly Reports.
Po Valley Energy Limited (“PVE” or “the Company”) is pleased to announce it has secured funding of $2.5m through the issue of a convertible note with a conversion price of $0.042 per share and a maturity of 3 years.
81 new crude and natural gas projects will start operations in Europe between 2018 and 2025. By 2025, the projects will contribute around 1,496 thousand barrels per day (mbd) to global oil production and close to 4.7 billion cubic feet per day (bcfd) to global gas production, according to GlobalData, a leading data and analytics company.
LNDNY OMVJF OMVZY OMVKY PVE LUPEY STOHF LNDNF STO
23h - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
23h - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
2018-08-20 - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...